Switch theme
Sign up to access all valuation multiples
Heartseed Inc is engaged in developing and commercializing iPS cell-derived cardiomyocyte replacement therapy for advanced heart failure.
2015
n/a
Last FY Revenue $6.0M
Last FY EBITDA -$5.3M
$366M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Heartseed achieved revenue of $6.0M and an EBITDA of -$5.3M.
Heartseed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Heartseed valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $6.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $6.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$5.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -89% | XXX | XXX | XXX |
| EBIT | XXX | -$7.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -119% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.6M | XXX | XXX | XXX |
| Net Margin | XXX | -93% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Heartseed's stock price is JPY 2626 (or $18).
Heartseed has current market cap of JPY 58.7B (or $403M), and EV of JPY 53.4B (or $366M).
See Heartseed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $366M | $403M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Heartseed has market cap of $403M and EV of $366M.
Heartseed's trades at 61.1x EV/Revenue multiple, and -68.8x EV/EBITDA.
Equity research analysts estimate Heartseed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Heartseed's P/E ratio is not available.
See valuation multiples for Heartseed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $403M | XXX | $403M | XXX | XXX | XXX |
| EV (current) | $366M | XXX | $366M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 61.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -68.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -51.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -72.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -37.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHeartseed's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Heartseed's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Heartseed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Heartseed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -89% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 219% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Heartseed acquired XXX companies to date.
Last acquisition by Heartseed was XXXXXXXX, XXXXX XXXXX XXXXXX . Heartseed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Heartseed founded? | Heartseed was founded in 2015. |
| Where is Heartseed headquartered? | Heartseed is headquartered in Japan. |
| Is Heartseed publicy listed? | Yes, Heartseed is a public company listed on TKS. |
| What is the stock symbol of Heartseed? | Heartseed trades under 219A ticker. |
| When did Heartseed go public? | Heartseed went public in 2024. |
| Who are competitors of Heartseed? | Similar companies to Heartseed include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Heartseed? | Heartseed's current market cap is $403M |
| Is Heartseed profitable? | Yes, Heartseed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
